Panbela Therapeutics announces issuance of new patent in US, Canada

Panbela Therapeutics announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled “EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION”. These patents claim a novel composition of a fixed dose combination of eflornithine and sulindac, which is called Flynpovi. The product was developed in collaboration with Sanofi, an innovative global healthcare company. Flynpovi is Panbela’s lead investigational product for the treatment of patients with Familial Adenomatous Polyposis. The patents are valid until 2036, have issued in the US, Australia, Mexico, Taiwan, and Chile. The application is under review in additional countries. Jennifer Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela Therapeutics, commented, “We’re excited to have this patent in Canada as well as the continuation in the US. Expansion of our patent portfolio further supports our global clinical programs. First issued in the United States in 2021 and now in several other territories, this patent covers the novel co-formulation of Flynpovi, our lead FAP product in development.”